Benitec Biopharma Inc reports results for the quarter ended in March - Earnings Summary

Benitec Biopharma

15/05/2023 14:47

* Benitec Biopharma Inc  BNTC.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in March. The
lone analyst forecast for the quarter was for a loss of 20 cents
per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Benitec Biopharma Inc's reported EPS for the quarter was a
loss
of 16 cents​.
    * The mean earnings estimate of analysts had fallen by
about 81.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Benitec Biopharma Inc shares had risen by 1.1% this
quarter and
gained 24.8% so far this year.
    * Wall Street's median 12-month price target for Benitec
Biopharma
Inc is $4.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 01:47 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.20          -0.16          Beat
 Dec. 31 2022      -0.11          -0.20          Missed
 Sep. 30 2022      -0.18          -0.47          Missed
 Jun. 30 2022      -0.28          -0.62          Missed